Implementation of routine Clostridioides difficile infection (CDI) primary prophylaxis in lung transplant recipients
Recommended Citation
Fitzmaurice MG, Hohlfelder B, Srinivas P, Rudoni M, Brizendine KD, and Budev M. Implementation of routine Clostridioides difficile infection (CDI) primary prophylaxis in lung transplant recipients. Clin Transplant 2023; e15079.
Document Type
Article
Publication Date
7-21-2023
Publication Title
Clinical transplantation
Abstract
Lung transplant recipients are at an increased risk for Clostridioides difficile infection (CDI), and those who develop CDI post-transplant can have worsened outcomes including graft failure and death. We sought to describe the efficacy and safety of primary CDI prophylaxis with oral vancomycin among 86 adult lung transplant recipients. Overall, we observed a 9.3% (8/86) incidence of CDI among patients receiving prophylaxis, with the majority of infections occurring a median of 25 days after completion of prophylaxis. Furthermore, we observed a 4.7% incidence of VRE infection/colonization. Opportunities exist to optimize the duration of CDI prophylaxis to balance the benefits and risks in lung transplant recipients.
PubMed ID
37477286
ePublication
ePub ahead of print
First Page
15079
Last Page
15079
